03/13/2026
Raise a seed round ...
(~$250,000) for the SecureFlow™ PD catheter stabilization strap
Below is a realistic capital use plan.
---
Capital Use Plan (Example: $250,000 Raise)
Category Budget Purpose
Product engineering & prototypes $45,000 Refine design, produce multiple prototypes for testing
Clinical feedback & usability testing $25,000 Feedback from dialysis nurses, nephrologists, and patients
Biocompatibility & safety testing $35,000 Required testing for skin-contact materials
Regulatory pathway preparation $20,000 FDA classification strategy and documentation
Patent & intellectual property $40,000 Provisional → non-provisional filing, claims expansion
Manufacturing preparation $30,000 Supplier sourcing, cost modeling, tooling samples
Business development & licensing outreach $25,000 Conferences, meetings with dialysis companies
Legal & corporate structure $10,000 Entity setup, licensing agreement preparation
Contingency reserve $20,000 Unexpected development costs
Total: ~$250,000
---
milestones:
1. Functional Product Prototype
Wearable PD catheter stabilization strap
Tested with real dialysis workflows
Ready for manufacturer evaluation
2. Protected Intellectual Property
Full patent application filed
Claims covering:
catheter stabilization
tension redistribution
wearable dialysis accessory
3. Licensing-Ready Device
Preliminary regulatory pathway defined
Basic safety testing completed
Manufacturing feasibility demonstrated
---
Typical Timeline for Use of Funds
Month Milestone
0–3 Prototype engineering + design refinement
3–6 Clinical usability testing
6–9 Biocompatibility testing
9–12 Licensing outreach to dialysis manufacturers
Goal: Secure licensing discussions within 12 months.
---
Expected Investor Return Mechanism
Investors typically receive:
Option A — Equity
15–20% ownership
Option B — Revenue share
% of licensing royalties until repayment multiple
Example:
$250k investment →
royalty revenue begins →
investor receives 2–3× return before dilution.
Accessory medical devices are attractive because they have:
lower regulatory risk
simple manufacturing
recurring use
clear clinical pain points
A successful licensing deal could generate royalties for 10–20 years.
---
If you'd like, I can also show
the exact 12-month development roadmap.
